Clinical Trial

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

Study acronym: BETWEEN
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study was design to: * To assess the impact of a biweekly (experimental arm) compared to a conventional administration (control arm) on the rate of grade 3-4 neutropenia in metastatic colorectal cancer (mCRC) patients treated with trifluridine/tipiracil plus bevacizumab, and * To identify predictive clinical and biological factors for grade 3-4 neutropenia in this patient population.
Trial Details
NCT Number NCT07071844
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborators: Servier
Conditions Metastatic Colorectal Cancer
Enrollment 162 participants
Start Date 2025-09
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-17